论文部分内容阅读
目的分析吉西他滨联合奥沙利铂治疗尿路上皮肿瘤的临床价值。方法将36例接受吉西他滨联合奥沙利铂治疗患者作为观察组,将35例吉西他滨联合顺铂治疗患者作为对照组,对比两组患者临床效果。结果观察组临床有效率61.1%,临床获益率91.7%;对照组临床有效率57.1%,临床获益率88.6%,无统计学意义(P>0.05),两组无疾病进展期对比(P>0.05),观察组白细胞减少、血小板减少、恶心呕吐路发生率明显低于对照组,P<0.05,其余不良反应对比,P>0.05。结论吉西他滨联合奥沙利铂治疗尿路上皮肿瘤效果显著,不良反应轻。
Objective To analyze the clinical value of gemcitabine plus oxaliplatin in the treatment of urothelial tumors. Methods Thirty-six patients receiving gemcitabine combined with oxaliplatin as the observation group and 35 patients receiving gemcitabine combined with cisplatin as the control group, the clinical effects were compared between the two groups. Results The clinical effective rate was 61.1% and the clinical benefit rate was 91.7% in the observation group. The clinical effective rate in the control group was 57.1% and the clinical benefit rate was 88.6%, with no statistical significance (P> 0.05) > 0.05). The incidences of leukopenia, thrombocytopenia and nausea and vomiting in the observation group were significantly lower than those in the control group (P <0.05). The remaining adverse reactions were compared, P> 0.05. Conclusion The combination of gemcitabine and oxaliplatin is effective in treating urothelial tumors, with mild adverse reactions.